Skip to main content

Table 3 Primary and secondary outcomes

From: Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial

OutcomesStandard-dose meropenem (n = 38)High-dose meropenem (n = 38)P value
Primary outcome
 Delta mSOFA score, median (IQR)− 1 (− 6 to 3)− 1 (− 9 to 4)0.746
  Delta respiratory score− 1 (− 3 to 2)− 1 (− 4 to 2)0.136
  Delta cardiovascular score0 (− 4 to 3)− 1 (− 4 to 3)0.599
  Delta liver score0 (− 1 to 2)0 (− 1 to 2)0.570
  Delta renal score0 (− 1 to 2)0 (− 2 to 1)0.201
  Delta coagulation score0 (− 2 to 3)0 (− 1 to 3)0.052
Secondary outcomes
 14-day mortality, n (%)6 (15.8)4 (10.5)0.736
 28-day mortality, n (%)17 (44.7)13 (34.2)0.482
 Clinical cure, n (%)33 (86.8)33 (86.8)1.000
 Microbiological cure, n (%)17 (44.7)21 (55.3)0.492
 Vasopressor-free days, median (IQR)24.5 (0–27)25 (0–27)0.350
 Ventilator-free days, median (IQR)11.5 (0–24)10.0 (0–28)0.819
 ICU-free days, median (IQR)0.5 (0–19)9.5 (0–20)0.819
 Hospital-free days, median (IQR)0 (0–74)37.5 (0–72)0.819
 Adverse events
  Diarrhea, n (%)12 (31.6)8 (21.1)0.435
  1. mSOFA modified sequential organ failure assessment score, ICU intensive care unit